The International Osteoporosis Foundation (IOF) Bone and Cancer Working Group has released a comprehensive review detailing the often under-recognized impact of modern anti-cancer treatments on bone health. It highlights the need to address cancer treatment-induced bone loss (CTIBL), including in patients undergoing cutting-edge therapies. The publication provides a review of the bone effects of major anti-cancer therapies currently in use, including newer agents, and discusses their known cellular impacts, effects on bone mineral density (BMD), and fracture incidence by drug category. Among the key messages: —Drugs such as glucocorticoids, hormone therapies, antiangiogenic drugs, and immune checkpoint inhibitors show varying degrees...